Serotonergic	serotonergic	O	O	O	O
drugs	drugs	O	O	O	O
,	,	O	O	O	O
benzodiazepines	benzodiazepines	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
baclofen	baclofen	O	O	OTHERS	I
block	block	O	O	O	O
muscimol-induced	muscimol-induced	O	O	O	O
myoclonic	myoclonic	O	DISEASE	OTHERS	I
jerks	jerks	O	DISEASE	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
strain	strain	O	O	O	O
of	of	O	O	O	O
mice	mice	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
male	male	O	O	O	O
Swiss	swiss	O	O	O	O
mice	mice	O	O	O	O
,	,	O	O	O	O
muscimol	muscimol	O	O	OTHERS	I
produced	produced	O	O	O	O
myoclonic	myoclonic	O	DISEASE	OTHERS	I
jerks	jerks	O	DISEASE	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
3	3	O	O	O	O
mg/kg	mg/kg	O	O	O	O
(	(	O	O	O	O
i.p	i.p	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
dose	dose	O	O	O	O
induced	induced	O	O	O	O
this	this	O	O	O	O
response	response	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
mice	mice	O	O	O	O
tested	tested	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
peak	peak	O	O	O	O
response	response	O	O	O	O
of	of	O	O	O	O
73	73	O	O	O	O
jerks	jerks	O	O	O	O
per	per	O	O	O	O
min	min	O	O	O	O
was	was	O	O	O	O
observed	observed	O	O	O	O
between	between	O	O	O	O
27	27	O	O	O	O
and	and	O	O	O	O
45	45	O	O	O	O
min	min	O	O	O	O
.	.	O	O	O	O

Increasing	increasing	O	O	O	O
the	the	O	O	O	O
brain	brain	O	O	O	O
serotonin	serotonin	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
5-hydroxytryptophan	5-hydroxytryptophan	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
80	80	O	O	O	O
-	-	O	O	O	O
160	160	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
combination	combination	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
peripheral	peripheral	O	O	O	O
decarboxylase	decarboxylase	O	O	O	O
inhibitor	inhibitor	O	O	O	O
resulted	resulted	O	O	O	O
in	in	O	O	O	O
an	an	O	O	O	O
inhibition	inhibition	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
muscimol	muscimol	O	O	OTHERS	I
effect	effect	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
similar	similar	O	O	O	O
experiment	experiment	O	O	O	O
l-dopa	l-dopa	O	O	O	O
(	(	O	O	O	O
80	80	O	O	O	O
-	-	O	O	O	O
160	160	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
was	was	O	O	O	O
without	without	O	O	O	O
effect	effect	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
3	3	O	O	O	O
-	-	O	O	O	O
10	10	O	O	O	O
mg/kg	mg/kg	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
serotonin	serotonin	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
agonist	agonist	O	O	O	O
MK-212	mk-212	O	O	OTHERS	I
caused	caused	O	O	O	O
a	a	O	O	O	O
dose-dependent	dose-dependent	O	O	O	O
blockade	blockade	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
response	response	O	O	O	O
of	of	O	O	O	O
muscimol	muscimol	O	O	OTHERS	I
.	.	O	O	O	O

Of	of	O	O	O	O
the	the	O	O	O	O
benzodiazepines	benzodiazepines	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
clonazepam	clonazepam	O	O	OTHERS	I
(	(	O	O	O	O
0.1	0.1	O	O	O	O
-	-	O	O	O	O
0.3	0.3	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
was	was	O	O	O	O
found	found	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
several	several	O	O	O	O
fold	fold	O	O	O	O
more	more	O	O	O	O
potent	potent	O	O	O	O
than	than	O	O	O	O
diazepam	diazepam	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
0.3	0.3	O	O	O	O
-	-	O	O	O	O
3	3	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
blocking	blocking	O	O	O	O
the	the	O	O	O	O
myoclonic	myoclonic	O	DISEASE	OTHERS	I
jerks	jerks	O	DISEASE	OTHERS	I
.	.	O	O	O	O

While	while	O	O	O	O
(-)-baclofen	(-)-baclofen	O	O	O	O
(	(	O	O	O	O
1	1	O	O	O	O
-	-	O	O	O	O
3	3	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
proved	proved	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
an	an	O	O	O	O
effective	effective	O	O	O	O
antagonist	antagonist	O	O	O	O
of	of	O	O	O	O
muscimol	muscimol	O	O	OTHERS	I
,	,	O	O	O	O
its	its	O	O	O	O
(+)-isomer	(+)-isomer	O	O	O	O
(	(	O	O	O	O
5	5	O	O	O	O
-	-	O	O	O	O
20	20	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
lacked	lacked	O	O	O	O
this	this	O	O	O	O
property	property	O	O	O	O
.	.	O	O	O	O

Considering	considering	O	O	O	O
the	the	O	O	O	O
fact	fact	O	O	O	O
that	that	O	O	O	O
5-HTP	5-htp	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
the	the	O	O	O	O
benzodiazepines	benzodiazepines	CHEMICALS	O	OTHERS	I
have	have	O	O	O	O
been	been	O	O	O	O
found	found	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
beneficial	beneficial	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
management	management	O	O	O	O
of	of	O	O	O	O
clinical	clinical	O	O	O	O
myoclonus	myoclonus	O	DISEASE	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
muscimol-induced	muscimol-induced	O	O	O	O
myoclonus	myoclonus	O	DISEASE	OTHERS	I
seems	seems	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
a	a	O	O	O	O
satisfactory	satisfactory	O	O	O	O
animal	animal	O	O	O	O
model	model	O	O	O	O
that	that	O	O	O	O
may	may	O	O	O	O
prove	prove	O	O	O	O
useful	useful	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
new	new	O	O	O	O
drug	drug	O	O	O	O
treatments	treatments	O	O	O	O
for	for	O	O	O	O
this	this	O	O	O	O
condition	condition	O	O	O	O
.	.	O	O	O	O

Our	our	O	O	O	O
present	present	O	O	O	O
study	study	O	O	O	O
indicated	indicated	O	O	O	O
the	the	O	O	O	O
possible	possible	O	O	O	O
value	value	O	O	O	O
of	of	O	O	O	O
MK-212	mk-212	O	O	OTHERS	I
and	and	O	O	O	O
(-)-baclofen	(-)-baclofen	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
management	management	O	O	O	O
of	of	O	O	O	O
clinical	clinical	O	O	O	O
myoclonus	myoclonus	O	DISEASE	OTHERS	I
.	.	O	O	O	O

